Background: Variable rates of HER2 protein overexpression and gene ... they had measurable lesions (n = 4) or elevated cancer antigen 125 level and non-measurable lesions (n = 3).

HER2 and EGF receptor. However, there is not a single validation of a molecular marker in CTCs that provides prognostic information or predicts response to cancer therapies. This review describes ...

Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death.

If enough tumor cells were collected during the FNA, we can also test for tumor markers. These breast cancer tumor markers include ER, PR, and HER2. They can help us predict how the cancer will ...

As we know, 65% to 70% of all breast cancers are HR-positive HER2-negative and this is also the most common subtype of metastatic breast cancer. The current standard of care for frontline therapy of ...

The company’s lead CAR-M program, CT-0508, will soon enter phase 1 testing, having shown increased overall survival in a preclinical model of HER2+ cancer. Carisma’s CAR-M therapies rest on a ...

One of them is relying on the HER2 protein, whose overexpression ... the first step is to identify a marker that is only present in tumor cells, an antigen that allows clear distinction from ...

We work closely with physician scientists and aim to apply our findings from basic research to the development of prognostic markers and therapeutics for the treatment ... Therapeutic resistance of ...

The EMA has started a review of AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC) that could see the drug being used in advanced breast cancer with even lower levels of the HER2 ...

Dawn Klemow, MD, assistant clinical professor, University of Texas Southwestern Medical Center, previews some of the most recent advances in breast cancer treatment.